Advances of blood cell-based drug delivery systems

Sun, Yanan; Su, Jing; Liu, Geyi; Chen, Jianjun; Zhang, Xiumei; Zhang, Ran; Jiang, Minhan; Qiu, Mingfeng

doi:10.1016/j.ejps.2016.07.021

Cited by 112 publications

(73 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These achievements (summarized in the next sections) are possible only thanks to the exclusive features of these cells which allow them to be engineered without altering their properties or compromising their in vivo circulation. In fact, the biochemical characteristics of RBC, their physiology as well as the molecular mechanisms governing the natural fate of the senescent or damaged cells, make them attractive candidates as carriers of conventional and/or new drugs, as extensively documented in recent, excellent, reviews . RBC are among the most abundant cell types in a human body: they comprise approximately one quarter of the total cell number and are the main component of blood with the crucial role of carriers of oxygen and carbon dioxide.…”

Section: Biology and Circulation Of Human Rbcmentioning

confidence: 99%

Reengineering red blood cells for cellular therapeutics and diagnostics

Pierigé

Bigini

Rossi

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Recently optimized technologies that permit the reversible opening of nanopores across the red blood cell membrane, give the extraordinary opportunity for reengineering human erythrocytes to be used in different biomedical applications, both for therapeutic and diagnostic purposes. Engineered erythrocytes have been exploited as a system for the controlled release of drugs in circulation upon encapsulation of prodrugs or small molecules; as bioreactors when they are endowed of recombinant enzymes able to catalyze the conversion of toxic metabolite into inert products; as drug targeting system for the delivery of compounds to the reticuloendothelial system inducing proper senescent signals on the drug-loaded erythrocyte membrane; as carrier of contrasting agents for diagnostic procedures. Preclinical development of these different applications has taken advantage from the use of proper animal models whose erythrocytes can be reengineered as the human ones or the encapsulation procedures can be adapted on the basis of their specific erythrocyte biological features. Successful results, obtained both in vitro and in preclinical studies, have prompted several clinicians to start pilot clinical investigations in different conditions and some new companies to start the industrialization of selected loading technologies and to initiate clinical development programs. This short review summarizes the key features that, to the best of our knowledge, have been crucial to advance the products toward regulatory clinical approval making reengineering of erythrocytes a modality to treat patients with limited or absent therapeutic options. WIREs Nanomed Nanobiotechnol 2017, 9:e1454. doi: 10.1002/wnan.1454 For further resources related to this article, please visit the WIREs website.

show abstract

Section: Biology and Circulation Of Human Rbcmentioning

confidence: 99%

Reengineering red blood cells for cellular therapeutics and diagnostics

Pierigé

Bigini

Rossi

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Release dynamics is crucial for the correct drug administration: it prevents the side effects of the treatment and keeps the efficiency of the drug. The application of DDS can enhance the therapeutic effects in sites where the pathology is located, limiting the potential cytotoxic effects of the drug on other specific tissues and maintaining the drug properties unmodified 2 . These characteristics make DDS particularly suitable for cancer treatments where the cytotoxicity levels of used drugs are, usually, high 3 …”

Section: Introductionmentioning

confidence: 99%

Exosome mediated transfer of miRNA‐140 promotes enhanced chondrogenic differentiation of bone marrow stem cells for enhanced cartilage repair and regeneration

Lee

Thangavelu

Choi

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…For the past few years, NPs prepared from SA as drug carrier systems have also attracted more attention [26,27]. Red blood cells membrane (RBCM) will be formed into vesicles (RVs) using extrusion or sonication methods [28]. As a drug carrier, it can be attached to the surface of NPs to sustain the release of drugs, avoid elimination by the immune system, increase drug stability, improve biocompatibility and thus prolong drug circulation in vivo [29,30].…”

Section: Introductionmentioning

confidence: 99%

Erythrocyte Membrane-Coated Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

Arsenic trioxide (ATO) has a significant effect on the treatment of acute promyelocytic leukemia (APL) and advanced primary liver cancer, but it still faces severe side effects. Considering these problems, red blood cell membrane-camouflaged ATO-loaded sodium alginate nanoparticles (RBCM-SA-ATO-NPs, RSANs) were developed to relieve the toxicity of ATO while maintaining its efficacy. ATO-loaded sodium alginate nanoparticles (SA-ATO-NPs, SANs) were prepared by the ion crosslinking method, and then RBCM was extruded onto the surface to obtain RSANs. The average particle size of RSANs was found to be 163.2 nm with a complete shell-core bilayer structure, and the average encapsulation efficiency was 14.31%. Compared with SANs, RAW 264.7 macrophages reduced the phagocytosis of RSANs by 51%, and the in vitro cumulative release rate of RSANs was 95% at 84 h, which revealed a prominent sustained release. Furthermore, it demonstrated that RSANs had lower cytotoxicity as compared to normal 293 cells and exhibited anti-tumor effects on both NB4 cells and 7721 cells. In vivo studies further showed that ATO could cause mild lesions of main organs while RSANs could reduce the toxicity and improve the anti-tumor effects. In brief, the developed RSANs system provides a promising alternative for ATO treatment safely and effectively.

show abstract

Advances of blood cell-based drug delivery systems

Cited by 112 publications

References 131 publications

Reengineering red blood cells for cellular therapeutics and diagnostics

Reengineering red blood cells for cellular therapeutics and diagnostics

Exosome mediated transfer of miRNA‐140 promotes enhanced chondrogenic differentiation of bone marrow stem cells for enhanced cartilage repair and regeneration

Erythrocyte Membrane-Coated Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Therapy

Contact Info

Product

Resources

About